The importance of carboxypeptidase U (CPU) as a novel regulator of the fibrinolytic rate has attracted much interest during recent years. CPU circulates in plasma as a zymogen, proCPU, that can be activated by thrombin, thrombin-thrombomodulin (TTm), or plasmin. Given that the proCPU concentration in plasma is far below its K m for activation by the T-Tm complex, the formation of CPU will be directly proportional to the proCPU concentration. A low or high proCPU plasma concentration might therefore tip the balance between profibrinolytic and antifibrinolytic pathways and thereby cause a predisposition to bleeding or thrombosis. Content: To measure plasma proCPU concentrations, different methods have been developed based on 2 different principles: antigen determination and measurement of CPU activity after quantitative conversion of the proenzyme to its active form by addition of T-Tm. The major drawbacks that should be kept in mind when analyzing clinical samples by both principles are reviewed. Conclusions: proCPU is a potential prothrombotic risk factor. Evaluation of its relationship with thrombosis requires accurate assays. Many assays used in different clinical settings are inadequately validated, forcing reconsideration of conclusions made in these reports.
enzyme carboxypeptidase U, the U standing for unstable. At that time, CPU was assumed to participate in the processing of bioactive peptides such bradykinin and anaphylatoxins by analogy with CPN, and a possible role in fibrinolysis was suggested (2, 4 -6 ) . In the following years the proCPU/CPU pathway was identified as an important coagulation-dependent pathway in the control of the fibrinolytic rate. By removing the C-terminal lysine residues on partially degraded fibrin, CPU prevents the acceleration of plasminogen binding and activation and promotes the inhibition of plasmin by ␣ 2 -antiplasmin (7) (8) (9) (10) . As long as the plasma CPU activity remains above a certain threshold value, fibrinolysis does not accelerate but stays in its initial phase (11, 12 ) . It has also been suggested that CPU is an acute-phase protein (13, 14 ) and that, in addition to its role in fibrinolysis, it plays a role in regulating inflammation (15) (16) (17) . Indeed, recent reports have suggested that CPU can cleave bradykinin and C5a-and thereby modulate their proinflammatory functions-as efficiently as plasmin-cleaved fibrin peptides (17 ) . Thrombin is believed to be the activator of proCPU in vivo, albeit with low catalytic efficiency in vitro. Thrombomodulin stimulates the rate of proCPU activation by thrombin 1250-fold (18, 19 ) . proCPU circulates in plasma at a concentration of 73-250 nmol/L (4.4 -15.0 g/mL) (20 -23 ) . Given that the proCPU concentration in plasma is far below its K m for activation by the thrombinthrombomodulin (T-Tm) complex, the formation of CPU will be dependent on both the T-Tm concentration and the proCPU concentration (18, 20 -23 ) . A low or high proCPU plasma concentration might therefore tip the balance between profibrinolytic and antifibrinolytic pathways and thereby cause a predisposition to bleeding or thrombosis. Plasma proCPU concentrations were therefore analyzed in different clinical settings. The proCPU in plasma can be measured by both immunologic assays (sandwich ELISA) or activity assays. In this brief review we will discuss the advantages and disadvantages of immunologic and activity-based assays and focus on the major drawbacks of those assays that should be kept in mind when clinical samples are analyzed. proCPU is a difficult protein to analyze in a laboratory. Research groups who are planning to analyze proCPU in clinical studies should be aware of those difficulties and pitfalls before they choose a analytical method to perform the proCPU measurements. Unfortunately, many clinical studies were performed in the past with inadequately validated assays, forcing reconsideration of conclusions made in those reports.
Antigen Assays
The most common way of measuring antigen concentrations is by immunoassay. Different research groups have developed in-house ELISAs, and currently, several commercial ELISAs are available (20 -24 ) . A rocket immunoelectrophoresis method was also described to measure proCPU antigen by use of rabbit anti-proCPU IgG (25 ) .
advantages
ELISAs are very easy to perform: no preliminary activation of the zymogen is required, and no interference of the constitutively active CPN is seen, which explain the widespread use of this assay format.
drawbacks
To understand the major pitfalls of the antigen assays, a few recently discovered characteristics should first be reviewed. Two functional proCPU variants have been described: the first variant differed from the published proCPU sequence at nucleotide 505 (G-to-A substitution producing an Ala-to-Thr substitution at position 147 in the protein) (26 ) . Brouwers et al. (27 ) described a second functional polymorphism at nucleotide 1040 (C-to-T substitution producing a Thr-to-Ile substitution at position 325 in the protein). This Thr325Ile polymorphism is of particular interest because the proCPU Ile325 variant has an extended functional half-life (28 ) . Because increased antifibrinolytic activity and, theoretically, a higher risk of thrombosis can be attributable to higher proCPU concentrations or to increased CPU stability (related to the Thr325Ile polymorphism), both polymorphisms have been investigated in different clinical studies. In addition to these polymorphisms, several polymorphisms in the 5Ј regulatory region, the promoter region, and the 3Ј untranslated region have been described (29, 30 ) . Some of these polymorphisms appear to be in strong association with plasma proCPU concentrations, which could imply differences in proCPU gene expression. The polymorphisms associated with proCPU plasma concentrations, however, are in strong linkage dysequilibrium with each other and with the 505A/G single-nucleotide polymorphism in the coding region (29, 30 ) . This Ala147Thr polymorphism has the strongest association with antigen concentrations but is also in strong linkage dysequilibrium with the Thr325Ile polymorphism (27 ) . Gils et al. (24 ) , however, recently demonstrated that the substitution of Ile for Thr at position 325 can have a large impact on the immunoreactivity of the isoform. From 144 monoclonal antibody combinations (which were tested according to differences in immunoreactivity), they developed 2 distinct ELISAs. The first ELISA was independent of the 325 genotype, but the second showed a complete lack of reactivity with the Ile/Ile genotype. Partial dependency of the 325 genotype was also seen with most of the commercially available ELISAs used in many clinical studies [e.g., 44 (8.9)% and 100 (30)% for the Ile/Ile and Thr/Thr isoforms, respectively, expressed as the mean (SD) percentage vs normal pooled plasma as measured by the commercially available Milan Analytica assay]. Thus, the association reported in several studies between the polymorphisms and proCPU antigen concentrations may reflect differences in assay sensitivity between isoforms rather than differences in expression. Although ELISAs are very attractive and very easy to use, great care should be taken. Assays should be very well characterized with respect to genotype-dependent reactivity.
In addition to the polymorphism issue, various proCPU and CPU forms are present in plasma (Fig. 1) . It is likely that antibodies raised against the zymogen can have different reactivities toward proCPU, proCPU bound to plasminogen, CPU, and conformationally and proteolytically inactivated forms of proCPU and CPU (23, 24, 31 ) . Although in plasma the protein will be present predominantly in its zymogen form, relevant amounts of active and subsequently inactivated enzyme can be expected in plasma from patients in whom the coagulation and fibrinolysis cascades are activated. Gils et al. (24 ) found different reactivities toward blotted On activation, CPU can be inactivated by a conformational change (t 1/2 ϭ 8 -15 min at 37°C). This 35-kDa fragment (iCPU) can then be cleaved at Arg-302 by thrombin (T) or plasmin (Pl), producing 24-and 11-kDa fragments. Antibodies used in ELISAs may not only react with proCPU, but can also recognize CPU, inactivated CPU, fragments of inactivated CPU (24-and 11-kDa), the 20-kDa propeptide (Pro), and some minor cleavage fragments.
proCPU fragments when they used 27 different monoclonal antibodies. For example, some antibodies reacted only with the 55-kDa proCPU, some with both the 55-and 35-kDa proCPU fragments, and others with the 55-, 35-, and 25-kDa proCPU fragments.
Standardization of the various assays is another critical issue. Different preparations of pooled plasma and purified proCPU used as calibrators in the different assays are probably one of the main reasons for the large variations in the mean plasma concentrations and ranges reported (32 ) . proCPU concentrations in pooled plasma varied from 73 nmol/L (4.4 g/mL) to 250 nmol/L (15 g/mL) (20 -22, 25 ) . Strö mqvist et al. (22 ) measured the plasma proCPU concentration in 479 apparently healthy volunteers and found a mean (SD) of 13.4 (2.5) g/mL, or 223 nmol/L.
Activity-Based Assays
Activity assays can be used as an alternative for antigen assays. Most of the assays are based on the fact that CPU can cleave a C-terminal arginine or lysine from a synthetic substrate. The cleaved arginine/lysine or the other fragment can be measured by different analytical methods. We will discuss the advantages and drawbacks of activity-based assays and will give an overview of the most important currently used methods.
advantages
A major advantage is that only the enzymatically active CPU is measured (after quantitative conversion of proCPU) without interference from inactivated CPU, the propeptide, and proteolytic fragments of CPU.
Another important advantage of activity assays compared with antigen assays is that the 2 described polymorphisms in the coding region of proCPU (Thr147Ala and Thr325Ile) have similar activation kinetics and the activated enzymes have similar carboxypeptidase B-like activity toward small synthetic substrates (26, 28 ) . Activity assays can therefore be used to study whether the reported association between the functional polymorphisms and proCPU concentrations is just a laboratory artifact attributable to different reactivities, as suggested by Gils et al. (24 ) , or whether there is indeed a significant association (32 ) . drawbacks proCPU is an inactive zymogen; therefore, accurate measurement of proCPU concentrations by activity-based assays requires quantitative conversion of the zymogen to CPU. Thus, a very well standardized activation protocol is required (18, 19 ) . Because most of the activity assays use synthetic substrates that are not selective for CPU, the interfering activity of plasma CPN must also be accounted for (33 ) . This makes activity-based assays more timeconsuming than antigen assays. Major drawbacks of this kind of assay include the intrinsic instability of CPU and the differences in stability among isoforms. CPU has a temperature-dependent instability with a half-life of 8 -10 min at 37°C in both serum and in the purified form, except for the recently described Ile325Ile polymorphism, which has a half-life of 15 min (28, 34 ) . Much evidence points to a structural change that accounts for the irreversible loss of activity (34 ) . Because of this instability, samples should be kept on ice after activation. CPU can be stabilized by the presence of excess substrate. At low substrate concentrations, however, the stabilizing effect of the substrate becomes negligible, and linear substrate conversion occurs during a very short time interval. When the incubation interval of an endpoint method is longer than this linear time interval, a significant fraction of the CPU will decay and the enzymatic velocity and, hence, proCPU concentration will be underestimated (35, 36 ) . These stability problems have been solved in the past by use of very high substrate concentrations (which stabilize the active enzyme) and by validating the linear time interval of substrate conversion, by incubating for short periods of time, or by incubating at room temperature (35, 36 ) . Another possibility for solving this problem is use of a continuously monitored reaction, which enables the determination of accurate initial velocities even at very low substrate concentrations (36, 37 ) .
Overview of Currently Used Activity-Based Assays hplc-assisted assay
The most sensitive activity-based assay for measuring proCPU is based on the HPLC-assisted quantification of hippuric acid liberated from hippuryl-l-arginine with o-methylhippuric acid as an internal standard (Fig. 2) (35 ) . On activation of the plasma samples by T-Tm, hippuryll-arginine is added in high excess (24 mmol/L; K m ϭ 0.84 mmol/L) to stabilize the active enzyme during the 30-min incubation at 37°C, after which the reaction is stopped with 1 mol/L HCl. After addition of the internal standard o-methylhippuric acid, the hippuric acid and internal standard are extracted with ethyl acetate, evaporated to dryness, and measured by HPLC using a C 18 column. Although this method is very sensitive, with a detection limit as low as 1 U/L, throughput is lower because it is very time-consuming. However, it is a method of first choice when high sensitivity is required, e.g., for checking the degree of depletion in proCPU-depleted plasma or measuring the generation of CPU during in vitro clot lysis in the absence of Tm. Using this method, Schatteman et al. (35 ) established a reference interval based on 490 healthy individuals: the mean (SD) proCPU concentration, expressed as CPU activity, was 964 (155) U/L (1 U of enzyme activity was defined as the amount of enzyme required to hydrolyze 1 mol of hippuryl-l-arginine per minute at 37°C under the conditions described). As discussed above, the 964 U/L corresponds to a proCPU concentration of 223 nmol/L (13.4 g/mL).
spectrophotometric endpoint activity assays
Typical assays for carboxypeptidase activity rely on a change of absorbance, and sensitivity is always an important issue. A widely used activity measurement is carboxypeptidase-mediated release of hippuric acid from either hippuryl-l-arginine or hippuryl-l-lysine with a concomitant increase in absorbance at 254 nm (Fig. 2) . In an alternative homogeneous assay, the released hippuric acid is chemically converted by cyanuric acid chloride and the absorbance is measured at 382 nm (Fig. 2) (38 ) . Because the cyanuric acid chloride reagent is toxic, this method is not widely used. A coupled enzymatic assay has also been described that uses hippuricase as auxiliary enzyme, providing a more sensitive absorbance measurement at 506 nm (Fig. 2) . The assay is based on the conversion of the zymogen by T-Tm, followed by measurement of the activity with p-hydroxy-hippuryl-l-arginine as substrate. The released p-hydroxyhippuric acid is quantified colorimetrically at 506 nm after enzymatic conversion by hippuricase and oxidation to the quinoneimine dye (39, 40 ) . The authors correlated the assay with the HPLC-assisted assay (r ϭ 0.979; n ϭ 25) and validated the linear interval of substrate conversion. This assay offers an alternative to the precise, but more cumbersome, HPLC-assisted assay in clinical laboratory settings.
kinetic spectrophotometric assays
Hydrolysis of the substrates hippuryl-l-arginine and hippuryl-l-lysine can be monitored continuously at 254 nm. The extinction coefficients for the 2 substrates and the change in absorptivity that occurs on hydrolysis of the substrates were determined by Boffa et al. (41 ) and were as follows:
A kinetic spectrophotometric method for the determination of basic carboxypeptidases was described using furyl-acrolyl peptides (42 ) . The principle of this method is that the absorbance maxima of these synthetic peptide substrates shift to the left (ultraviolet) when the C-terminal arginine or lysine is cleaved by the carboxypeptidase. However, the strong background absorbance of the furyl-acrolyl peptide products compromises the sensitivity and accuracy of the assay. An anisylazoformyl chromophore that showed low product absorbance and improved sensitivity has been described (43, 44 ) . Recently, Willemse et al. (36, 37 ) published a rapid coupled enzymatic assay for measuring CPU activity with C-terminal arginine-containing peptides as substrate. After activation of proCPU by T-Tm, the resulting CPU activity cleaves a substrate with a C-terminal argi- nine. Arginine kinase phosphorylates the generated arginine, using ATP as a cofactor. The ATP used in this reaction is regenerated by pyruvate kinase, which catalyzes the transfer of the reactive phosphorus in phosphoenolpyruvate to ADP. The final step in this coupled enzymatic assay is the reduction of pyruvate to lactate by lactate dehydrogenase with concomitant oxidation of NADH, which can be monitored continuously at 340 nm. The assay was validated against the HPLC-assisted assay (r ϭ 0.956; n ϭ 56) and showed comparable reproducibility (within-and between day CVs, 2% and 3.9%, respectively) (37 ) . The advantage of kinetic determination of CPU activity is that there is no need to use an excess of substrate. A specific advantage of the kinetic assay described by Willemse et al. (36 ) is that it can be modified easily to allow the use of other C-terminal-argininecontaining substrates, and thus, alternative substrates (even physiologic) can be used. With this method it is possible to search for very selective CPU substrates so that correction for the interfering CPN activity-an important drawback of activity assays-could be avoided in the future (work in progress).
Conclusions
In recent years, considerable debate has arisen on the correct measurement of proCPU in plasma; this problem is discussed annually in the Scientific Standardisation Committee Meeting on fibrinolysis of the International Society of Thrombosis and Hemostasis. Plasma proCPU can be measured by antigen (ELISA) or by functional (activity) assays. Activity assays are considered by many groups as a secondary concern because of the prerequisite for quantitative activation of the zymogen and the need to correct for the interference by plasma CPN. In addition, the intrinsic instability of CPU complicates activity assays: samples should be kept on ice after activation, high substrate concentrations should be used to stabilize the enzyme during the assay, and the time interval of linear substrate conversion should be very well validated. Because of its instability, underestimation of CPU activity, and hence the proCPU concentration, is a major concern when using assays that lack adequate validation. It is therefore understandable that many clinical research groups who are not familiar with enzymatic assays prefer the use of ELISAs. Several ELISAs entered the market, and those commercially available ELISAs became the most important tool to analyze proCPU concentrations in clinical samples. Recently however, Gils et al. (24 ) reported that most of the currently available commercial antigen assays seem to be partially dependent on the naturally occurring Thr325Ile genotype. The findings of Gils et al. (24 ) compromise the interpretation of several epidemiologic studies evaluating proCPU antigen concentrations as a risk marker for cardiovascular events and force reconsideration of previously made conclusions. For example, a case-control study (using an activity-based assay) of patients with stable angina pectoris showed significantly higher proCPU concentrations in patients compared with controls (45 ) . In contrast, the HIFMECH study group reported that high (above the 90th percentile) proCPU antigen concentrations (measured with a commercial ELISA) may be protective for myocardial infarction (46 ) . Because there is a difference in sensitivity for the various isoforms among assays, ELISAs should be used very carefully and should be very well characterized with respect to genotype-dependent reactivity before they enter the market. In addition, conclusions regarding association of single-nucleotide polymorphisms with proCPU antigen concentrations in plasma should be reconsidered. Standardization of the various assays is another critical issue. The use of different preparations of pooled plasma and purified proCPU as calibrators in the various assays probably contributes considerably to the large variations in the mean plasma concentrations and ranges reported. proCPU concentrations in pooled plasma varied from 73 nmol/L (4.4 g/mL) to 250 nmol/L (15 g/mL) (20 -22, 25 ) .
In summary, we can state that antigen assays-when they are very well characterized regarding genotype-dependent reactivity-are an easy way to measure proCPU concentrations, whereas activity assays-although they are more time-consuming-are a very good alternative for measuring proCPU. Some research groups showed a good correlation between ELISAs and activity assays (21) (22) 24 ) . The most important advantage of activity assays compared with antigen assays is that the 2 described polymorphisms in the coding region of proCPU (Thr147Ala and Thr325Ile) have similar activation kinetics and the activated enzymes have similar carboxypeptidase B-like activity toward small synthetic substrates (26, 28 ) . In addition, inactivated CPU and enzymatically inactive fragments (e.g., the propeptide and proteolytic fragments) do not interfere in activity assays. A well-standardized activation protocol should be used, and the intrinsic instability of the enzyme should be taken in account. Recently, a kinetic assay was described by our group that allows the use of many different C-terminal-arginine substrates even at very low substrate concentrations (36, 37 ) . This assay could be used to search for more sensitive and selective CPU substrates that may eliminate the need to correct for interfering CPN activity, making activity-based assays more attractive and less time-consuming (36 ).
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